New study reveals opportunity for greater partnerships to improve medicines use for people with dementia
Results highlight role community pharmacy can play in medicines optimisation for residents with dementia in care homesi
4th June 2014
Published today, results of a large-scale audit of a two year service pilot reveal the positive role specially trained pharmacists can play in collaboration with GPs, nurses and care home workers in better managing the appropriate use of antipsychotic medicines for people with dementia in care homes.
According to the study, through the use of specially trained pharmacists in a pilot service, over one quarter (26%) of residents reviewed did not have any symptoms which necessitated a regular anti-psychotic medication, and in almost two thirds (58%) of cases the risk of the medication was deemed to outweigh the benefit.i In addition, the audit resulted in over 20% of residents having their anti-psychotic dose reduced, and more than 17% realising antipsychotic medication discontinuation. The audit was undertaken by selected Boots UK pharmacists, some of whom had received additional Alzheimer’s Society training to enable them to better support people with dementia and carers.
Alistair Burns, National Clinical Director for Dementia at NHS England comments:
“The prescribing of antipsychotic drugs in people with dementia is associated with increased mortality and morbidity. This exciting publication underscores the key role that pharmacists have in optimising prescription of medication in this potentially vulnerable population.”
The study was commissioned by Boots UK in order to demonstrate the potential added value that community pharmacy can offer, and the significant contribution this service could make to the NHS. The pilot service demonstrates how the commissioning of pharmacy services could help further improve the care of vulnerable patients who live in residential care homes, working in partnership with other healthcare professionals. Since this audit was undertaken, the government has launched […]